AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 15, 2022 07:00 ET
|
AIM ImmunoTech Inc.
– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones – Cash position expected to fund operations through end of 2023 ...
AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
November 14, 2022 07:00 ET
|
AIM ImmunoTech Inc.
– Data selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting – Treatment was well tolerated, with promising clinical activity of pathologic complete...
AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy
February 16, 2021 09:15 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Feb. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has received approval from the required Ethics Committee in the Netherlands to...
Hemispherx Human Safety Study of Intranasal Ampligen® with Influenza Vaccine Shows Ampligen was Generally Well-Tolerated
August 14, 2017 08:30 ET
|
LinkedIn
PHILADELPHIA, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that it has commenced full data analysis of an intranasal human safety study of Ampligen® plus FluMist®...
Hemispherx Biopharma Repurposes Ampligen in Immuno-Oncology
May 31, 2017 12:03 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, May 31, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the “Company") announced today that it continues to bolster its scientific capabilities by...
Hemispherx Biopharma Enhances Ampligen Manufacturing and Scientific Capabilities
May 31, 2017 11:38 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, May 31, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the “Company") announced today that it continues to build its manufacturing and scientific...
Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2017
May 15, 2017 17:23 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, May 15, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended March 31, 2017. The net loss was approximately...
Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2016
March 31, 2017 18:19 ET
|
Hemispherx Biopharma, Inc.
Hemispherx Biopharma Management Team Continues Its Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder Value Conference Call...
Hemispherx Biopharma, Inc. Meets Ampligen Sales Milestone in the 1st Quarter of 2017
March 06, 2017 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, March 06, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it has met a major milestone, the commencement of...
Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen®) for Sale to Early Access Program in Europe
January 26, 2017 10:51 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that an order of newly manufactured rintatolimod (Ampligen®) for sale utilizing the Early Access...